Evecxia Therapeutics
Manufacturing · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Davis Dr, Durham, North Carolina, 2770...Phone Number
(919) 597-8762Website
www.evecxia.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Evecxia Therapeutics
Evecxia Therapeutics is focused on harnessing the therapeutic potential of 5-hydroxytryptophan (5-HTP) to treat mental illness, aiming to improve the lives of those affected by disabling conditions inadequately addressed by current therapies. The company is pioneering serotonin synthesis amplification as a novel approach to enhance mood and reduce negative behaviors associated with mental disorders. Evecxia is developing proprietary drug delivery technologies to optimize the therapeutic effects of 5-HTP, making it a viable treatment option. Their mission is to help individuals lead fuller, more meaningful lives by addressing the limitations of existing antidepressant medications.Explore more
Evecxia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evecxia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Evecxia Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Evecxia Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Evecxia Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Evecxia Therapeutics launches new products
Funding: Get notified immidiatlly once Evecxia Therapeutics has new funding data
Check out if Evecxia Therapeutics is spiking on competitors!
Evecxia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Evecxia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Evecxia Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Evecxia Therapeutics
Compare insights from companies similar to Evecxia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Evecxia Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Evecxia Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Evecxia Therapeutics.
Evecxia Therapeutics financials insights
Gather financial insights about Evecxia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$4.6M
Evecxia Therapeutics Tech Stack
A closer look at the technologies used by Evecxia Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Project
Intellectual Property, Legal Affairs, Pharmaceuticals
Project
Product Management, Intellectual Property, Clinical Operations
Executive Move
Board of Directors
Executive Move
Board of Directors
Evecxia Therapeutics News & Media
Evecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 For Depression
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat central nervous system disorders—today announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Psychiatry, Office of Neuroscience, Center for Drug Evaluation and Research. FDA Feedback & Guidance The focus of the pre-IND meeting wasEvecxia Therapeutics ACCESS CHINA Partnering Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat CNS disorders—today announced Dr. Jacob Pade Ramsøe Jacobsen, the Co-Founder & Chief Executive Officer of Evecxia Therapeutics, Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. Link to ACCESS CHINA. About Evecxia Therapeutics EvEvecxia Therapeutics Files Patent for 5-hydroxytryptophan (5-HTP) Chemical Synthesis
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics files patent on a novel chemical synthesis process for 5-HTP, expected to secure 5-HTP drug substance supply, augment IP.Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat neuropsychiatric disorders, today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry. “We welcome Allan and Elliot to our team. We are excited to draw on their impressive backgrounds as we continue to progress Evecxia’s drug candidates thr
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evecxia Therapeutics
Sign Up For FreeTo access detailed company insights
Evecxia Therapeutics is focused on harnessing the therapeutic potential of 5-hydroxytryptophan (5-HTP) to treat mental illness, aiming to improve the lives of those affected by disabling conditions inadequately addressed by current therapies. The company is pioneering serotonin synthesis amplification as a novel approach to enhance mood and reduce... Read More
